The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-Cell recovery and persistent B-Cell activation

S.J. Brunt; S. Lee; L.J. D’Orsogna; C. Bundell; S. Burrows; P. Price

doi:10.1155/2014/947432

Back

The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-Cell recovery and persistent B-Cell activation

Journal article

Peer reviewed

The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-Cell recovery and persistent B-Cell activation

S.J. Brunt, S. Lee, L.J. D’Orsogna, C. Bundell, S. Burrows and P. Price

Disease Markers, Vol.2014, pp.1-8

2014

DOI: https://doi.org/10.1155/2014/947432

Files and links (1)

url

Free to Read *No subscription requiredView

Abstract

Objectives. Elevated humoral responses to cytomegalovirus (CMV) associate with increased risk of cardiovascular disease (CVD) in HIV patients on antiretroviral therapy (ART). To better understand the persistence of CMV humoral responses in relation to CVD, we determined trends in CMV antibody levels over the first 10 years on ART. Design. We describe longitudinal analyses of plasma from 13 HIV patients commencing ART with <210 CD4 T-cells/µL and 27 controls. Antibodies reactive with CMV (fibroblast lysate, gB and IE-1 antigens), EBV-VCA, and HIVgp41 were quantitated. B-cell activation was assessed via total IgG and sBAFF. Inflammation was assessed via sTNF-RI and sCD14. Results. Amongst CMV seropositive HIV patients, levels of antibody reactive with CMV (P=0.03) and EBV-VCA (P=0.02) peaked after 1 year on ART. Levels of total IgG, sCD14, and sTNF-RI declined to approximate those in controls after 10 years, but sBAFF (P=0.0002), EBV-VCA (P=0.02), and CMV (P=0.0004) antibodies remained elevated. A strong correlation between sBAFF and CMVgB antibody was seen at 10 years (R=0.93), P=0.0009) and verified in a second cohort. Conclusions. CMV antibody titres peak on ART and remain high. A correlation between CMV antibody and sBAFF suggests a role for HIV-induced B-cell pathology that may affect its use as a marker of CMV burden.

Details

Title: The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-Cell recovery and persistent B-Cell activation
Authors/Creators: S.J. Brunt (Author/Creator) - The University of Western Australia
S. Lee (Author/Creator) - Royal Perth Hospital
L.J. D’Orsogna (Author/Creator)
C. Bundell (Author/Creator) - Pathwest Laboratory Medicine
S. Burrows (Author/Creator) - The University of Western Australia
P. Price (Author/Creator) - School of Pathology and Laboratory Medicine
Publication Details: Disease Markers, Vol.2014, pp.1-8
Publisher: Hindawi Publishing
Identifiers: 991005542446007891
Copyright: © 2014 Samantha J. Brunt et al.
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

23 Record Views

15 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.161 Virology - Identification & Sequencing; 1.161.711 Cytomegalovirus Infections
Web Of Science research areas: Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology
ESI research areas: Clinical Medicine